ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE American: SYN), a diversified
clinical-stage company developing therapeutics designed to treat
diseases in areas of high unmet need, today announced that the
Company will be presenting at the 2022 BIO CEO & Investor
Conference being held February 14-17,
2022. The conference will be conducted as a hybrid event at
the New York Marriott Marquis and virtually.
Steven Shallcross, Chief
Executive Officer and Chief Financial Officer of Synthetic
Biologics is scheduled to present on Tuesday February 15, 2022 at 11:00 AM Eastern Time. Management will also be
available to participate in 1x1 meetings with qualified investors
throughout the conference. Synthetic's presentation will be made
available on their website at
https://ir.syntheticbiologics.com/.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is diversified
clinical-stage company developing therapeutics designed to treat
diseases in areas of high unmet need. The Company recently
announced it has entered into a definitive agreement to acquire VCN
Biosciences, S.L. (VCN), which is developing a new oncolytic
adenovirus (OV) platform designed for intravenous (IV) delivery to
trigger tumor cell death and promote immune cell infiltration into
tumors. The transaction is expected to close during the first
quarter of 2022, and is subject to, among other things, the
approval by the Spanish government of the Company's acquisition of
VCN under Spain's Foreign
Investment Act and other customary closing conditions. In addition,
the Company's lead candidates are: (1) SYN-004 (ribaxamase) which
is designed to degrade certain commonly used intravenous (IV)
beta-lactam antibiotics within the gastrointestinal (GI) tract to
prevent (a) microbiome damage, (b) Clostridioides
difficile infection (CDI), (c) overgrowth of pathogenic
organisms, (d) the emergence of antimicrobial resistance (AMR), and
(e) acute graft-versus-host-disease (aGVHD) in allogeneic
hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a
recombinant oral formulation of the enzyme intestinal alkaline
phosphatase (IAP) produced under cGMP conditions and intended to
treat both local GI and systemic diseases. For more information,
please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-2022-bio-ceo--investor-conference-301478423.html
SOURCE Synthetic Biologics, Inc.